Sugi Predict

Sugi Predict / Compounds / SCHEMBL49317

SCHEMBL49317

SCHEMBL49317

Clc1nc(Oc2ccccc2)nc(Oc2ccccc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAX8 Q06710 1/20 0.53
▸ KDM4E B2RXH2 3/20 0.50
▸ LTA4H P09960 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ KMT2A Q03164 5/20 0.47
▸ SMN1; SMN2 Q16637 5/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ POLB P06746 2/20 0.43
▸ GLA P06280 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ PIN1 Q13526 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639470 0.95 KDM4E (0.50) PAX8KDM4ELTA4HTSHRKMT2A
SCHEMBL11859472 0.90 MEN1 (0.53) PAX8KDM4ELTA4HTSHRKMT2A
SCHEMBL32688290 0.90 MEN1 (0.53) PAX8KDM4ELTA4HTSHRKMT2A
SCHEMBL1006428 0.88 PAX8 (0.63) PAX8KDM4ELTA4HTSHRKMT2A
SCHEMBL19295184 0.88 MEN1 (0.50) PAX8KDM4EKMT2ASMN1; SMN2MEN1
SCHEMBL17486267 0.86 LMNA (0.46) PAX8KDM4ELTA4HTSHRKMT2A
SCHEMBL24262518 0.85 KMT2A (0.61) PAX8KDM4ELTA4HTSHRKMT2A
SCHEMBL11240553 0.85 KDM4E (0.53) PAX8KDM4EKMT2ASMN1; SMN2MEN1
SCHEMBL16086043 0.84 PIN1 (0.43) PAX8KDM4EKMT2ASMN1; SMN2MEN1
SCHEMBL11772246 0.84 MEN1 (0.50) PAX8KDM4EKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813710-A Preparation method of carfilzomib 重庆药友制药有限责任公司 2023-09-29 — — CN claimed
CN-116768972-A Preparation method of carfilzomib intermediate 重庆药友制药有限责任公司 2023-09-19 — — CN claimed
EP-3464319-A2 INTERMEDIATES AND PROCESSES TO PREPARE ANIDULAFUNGIN Alaparthi, Lakshmi Prasad (IN) 2019-04-10 — — EP claimed
EP-3226885-A2 INTERMEDIATES AND PROCESSES TO PREPARE MICAFUNGIN Alaparthi, Lakshmi Prasad (IN) 2017-10-11 — — EP claimed
WO-2016056022-A2 INTERMEDIATES AND PROCESSES TO PREPARE ANIDULAFUNGIN ALAPARTHI LAKSHMI PRASAD (IN) 2016-04-14 — — WO claimed
WO-2016056023-A2 INTERMEDIATES AND PROCESSES TO PREPARE MICAFUNGIN ALAPARTHI LAKSHMI PRASAD (IN) 2016-04-14 — — WO claimed
US-8946475-B2 Processes for preparing a polymeric compound CELLCEUTIX CORPORATION (US) 2015-02-03 — — US claimed
EP-1912951-B1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA (DE) 2010-01-06 — — EP claimed
US-7608722-B2 Preparation of 1,7,′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-27 — — US claimed
EP-1912951-A1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-04-23 — — EP claimed
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-15 — — US claimed
WO-2007009967-A1 PREPARATION OF 1,7′-DIMETHYL-2′-PROPYL-2,5′-BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-25 — — WO claimed
US-4046735-A Stabilizers of nitrile polymers using triazine derivatives MONSANTO COMPANY (US) 1977-09-06 — — US claimed
CN-116813710-B Preparation method of carfilzomib 重庆药友制药有限责任公司 2024-07-12 — — CN disclosed
US-20230403927-A1 AROMATIC COMPOUNDS UDC IRELAND LTD (IE) 2023-12-14 — — US disclosed
US-20230403927-A1 AROMATIC COMPOUNDS UDC IRELAND LTD (IE) 2023-12-14 — — US disclosed
US-4234707-A Polymeric light stabilizers for plastics CIBA-GEIGY CORPORATION (US) 1980-11-18 — — US disclosed
US-4197388-A TRIAZINE CATALYST AKZONA INCORPORATED (US) 1980-04-08 — — US disclosed
US-4124763-A A,A'-DIARYL-A,A'-BIS(DISUBSTITUTED-TRIAZINYL)-SUCCINONITRILES AKZONA INCORPORATED (US) 1978-11-07 — — US disclosed
US-4046735-A Stabilizers of nitrile polymers using triazine derivatives MONSANTO COMPANY (US) 1977-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230403927-A1 AROMATIC COMPOUNDS TYR, CTCF, MITF PAX8 1641/4885KDM4E 1344/4885LTA4H 3670/4885
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) PNMT, PAM, PAH PAX8 4303/4885KDM4E 706/4885LTA4H 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.